Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus Venetoclax

1 Feb 2025

Abstract excerpt

BACKGROUND: The combination of venetoclax + azacitidine (VenAza) has become the standard frontline treatment for older unfit AML patients. METHODS: We analyzed outcomes using VenAza for previously untreated unfit AML patients at a single center between 2020-2024. RESULTS: The overall response rate (ORR) was 69/105 (66%), was highest for patients with NPM1 (78%) and IDH1/2 (82%) mutations and lowest with TP53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40023757
DOI: 10.1016/j.clml.2025.01.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxPMID 40023757Read ↗

Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity Read ↗

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.Semantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.Semantic proximity Read ↗

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive ChemotherapySemantic proximity Read ↗

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.